Regeneron Must Defend Against Drug Discount Fraud Lawsuit (1)

The US government can continue to allege that Regeneron Pharmaceuticals Inc. violated the False Claims Act by overcharging Medicare for its drug Eylea, which is used to treat age-related vision impairment, a federal district court said.

The government’s complaint adequately alleged that Regeneron submitted false average sales price reports that caused—and were material to—the submission of false claims for payment at falsely inflated prices, Judge Patti B. Saris of the US District Court for the District of Massachusetts said in a Tuesday order denying the company’s motion to dismiss.

Whistleblowers Julianne Nunnelly and Matthew Shanks filed this suit under seal ...